Adding radiotherapy to maintenance immunotherapy for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding radiation therapy to the chest during maintenance immunotherapy can help people with extensive-stage small cell lung cancer live longer. You may be eligible if you've already had chemotherapy plus immunotherapy and your cancer has shrunk or stayed stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer (cancer that has spread beyond one lung).
- You have completed 4-6 cycles of initial chemotherapy plus an immunotherapy drug, and your cancer has responded or stayed stable.
- You are in good enough health to go about daily activities (ECOG score 0 or 1).
- You have not had radiation therapy to the chest before.
- You do not have a history of lung inflammation (interstitial lung disease) or active pneumonia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This trial is testing a new approach for extensive-stage small cell lung cancer (SCLC) that has not been treated before. It combines a high-dose chemotherapy regimen with a drug called adebrelimab (an immunotherapy) and a stem cell transplant to help your body recover. The goal is to see if this powerful combination can work better than standard treatment.
This trial tests whether adding radiation therapy to standard immune therapy (atezolizumab) after initial chemo can help people with extensive-stage small cell lung cancer live longer and control the cancer better. You must have a good response (partial response) or stable disease after initial treatment, plus several lab/imaging checks to confirm safety.
This study tests whether adding radiation to the chest area can improve the effectiveness of maintenance immunotherapy (atezolizumab) in patients with extensive-stage small cell lung cancer who have responded well to initial treatment.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial adds total body irradiation (a low dose of radiation to the whole body) to standard atezolizumab (immunotherapy) plus chemotherapy for people with extensive-stage small cell lung cancer. The goal is to see if the radiation helps the immunotherapy work better.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.